Cancer Letters
Volume 203, Issue 2 , Pages 225-231 , January 2004

Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma

Received 26 February 2003 ,Revised 26 August 2003 ,Accepted 22 September 2003.

References 

  1. van Endert PM. Genes regulating MHC class I processing of antigen. Curr. Opin. Immunol. 1999;11:82–88
  2. Cresswell P, Bangia N, Dick T, Diedrich G. The nature of the MHC class I peptide loading complex. Immunol. Rev. 2000;172:21–28
  3. Zhang Q, Salter SD. Distinct patterns of folding and interactions with calnexin and calreticulin in human class I MHC proteins with altered N-glycosylation. J. Immunol. 1998;160:831–837
  4. Degen E, Cohen-Doyle MF, Williams DB. Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both beta 2-microglobulin and peptide. J. Exp. Med. 1992;175:1653–1661
  5. Sugita M, Brenner MB. An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J. Exp. Med. 1994;180:2163–2171
  6. Nossner E, Parham P. Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules. J. Exp. Med. 1995;181:327–337
  7. Tector M, Salter RD. Calnexin influences folding of human class I histocompatibility proteins but not their assembly with beta 2-microglobulin. J. Biol. Chem. 1995;270:19638–19642
  8. Rajagopalan S, Brenner MB. Calnexin retains unassembled major histocompatibility complex class I free heavy chains in the endoplasmic reticulum. J. Exp. Med. 1994;180:407–412
  9. Diedrich G, Bangia N, Pan M, Cresswell P. A role for calnexin in the assembly of the MHC class I loading complex in the endoplasmic reticulum. J. Immunol. 2001;166:1703–1709
  10. van Leeuwen JEM, Kearse KP. Deglucosylation of N-linked glycans is an important step in the dissociation of calreticulin-class I-TAP complex. Proc. Natl Acad. Sci. USA. 1996;93:13997–14001
  11. Harris MR, Yu YYL, Kindle CS, Hansen TH, Solheim JC. Calreticulin and calnexin interact with different protein and glycan determinants during the assembly of MHC class I. J. Immunol. 1998;160:5404–5409
  12. Sadasivan B, Lehner PJ, Orthmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 1996;5:103–114
  13. Solheim JC, Carreno BM, Hansen TH. Are transporter associated with antigen processing (TAP) and tapasin class I MHC chaperones?. J. Immunol. 1997;158:541–543
  14. Lewis JW, Elliott T. Evidence for successive peptide binding and quality control stages during MHC class I assembly. Curr. Biol. 1998;8:717–720
  15. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 1995;16:487–494
  16. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res. 1998;48:1019–1025
  17. van Duinen SG, Ruiter DJ, Broecker EB, Restifo NP, Marincola FM, Kawakami Y, et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 1996;88:100–108
  18. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma. Am. J. Pathol. 1999;154:745–754
  19. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, et al.  Immunoenzymatic labeling of monoclonal antibodies of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complex). J. Histochem. Cytochem. 1984;32:219–229
  20. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 2001;108:669–678
  21. Rauch F, Prud'homme J, Arabian A, Dedhar S, St-Arnaud R. Heart, brain, and body wall defects in mice lacking calreticulin. Exp. Cell. Res. 2000;256:105–111
  22. Gao B, Adhikari R, Howarth M, Nakamura K, Gold MC, Hill AB, et al.  assembly and antigen-presenting function of MHC class I molecules cells lacking the ER chaperone calreticulin. Immunity. 2002;16:99–109
  23. Turnquist HR, Vargas SE, McIlhaney MM, Li S, Wang P, Solheim JC. Calreticulin binds to the alpha1 domain of MHC class I independently tapasin. Tissue Antigens. 2002;59:18–24
  24. Nair S, Wearsch PA, Mitchell DA, Wasserberg JJ, Gilboa E, Nicchitta CV. Calreticulin displays in vivo peptide-binding activity and can elicit responses against bound peptides. J. Immunol. 1999;162:6426–6432
  25. Cheng WF, Hung CF, Chai CY, Scott JE, Dawson JR. MHC class I expression and transort in a calnexin-deficient cell line. J. Immunol. 1995;155:143–148
  26. Sadasivan BK, Cariappa A, Waneck GL, Cresswell P. Assembly, peptide loading, and transort of MHC class I molecules in a clanexin-negative cell line. Cold Spring Habor Symp. Quant. Biol. 1995;60:267–275
  27. Danilczyk UG, Cohen-Doyle MF, Williams DB. Functional relationship between calreticulin, calnexin, and the endoplasmic reticulum luminal domain of calnexin. J. Biol. Chem. 2000;275:13089–13097
  28. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int. J. Oncol. 2001;19:1211–1220
  29. Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, et al. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res. 2003;13:371–377
  30. Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003;13:253–258

PII: S0304-3835(03)00667-0

doi: 10.1016/j.canlet.2003.09.036

Cancer Letters
Volume 203, Issue 2 , Pages 225-231 , January 2004

Article Tools

* Image Usage & Resolution